TAMMY POPE: Open Payments
NPI 1407810062 · SHERIDAN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$204 in 11 payments from 7 companies in 2025. Trend: 2023 $267 · 2024 $246 · 2025 $204
Food & beverage: $204
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| Novo Nordisk Inc | 2 | $37 |
| Lilly USA, LLC | 2 | $30 |
| GlaxoSmithKline, LLC. | 2 | $29 |
| Abbott Laboratories | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
Products named: AIRSUPRA, TRELEGY ELLIPTA, CARDIOMEMS, REXULTI, YUPELRI, Rybelsus, MOUNJARO, ZEPBOUND.
Industry payments across AR — which companies pay providers there.
